US 11708416
Methods of treating severe insulin resistance by interfering with glucagon receptor signaling
granted A61KA61K2039/505A61K2039/507
Quick answer
US patent 11708416 (Methods of treating severe insulin resistance by interfering with glucagon receptor signaling) held by REGENERON PHARMACEUTICALS, INC. expires Mon Jul 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Jul 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 11
- CPC classes
- A61K, A61K2039/505, A61K2039/507, A61K2039/54, A61K2039/545